MiMedx Issues New Presentation for Investors in Advance of 2018 Annual Meeting Illustrates Key Events and Steps the Board Has Taken in Response to Allegations of Misconduct by Certain Members of the Company s Former Mana

MiMedx Issues New Presentation for Investors in Advance of 2018 Annual Meeting

Illustrates Key Events and Steps the Board Has Taken in Response to Allegations of Misconduct by Certain Members of the Company s

Former Management, Including Former Chairman and CEO Parker H. Pete Petit

Highlights Why the Company Believes

Mr. Petit is Unfit to Serve on the Board and Why Electing Him and

His Nominees Would Risk Derailing the Significant Progress

Shareholders Are Urged to Vote FOR All of the Board s Qualified Nominees

on the BLUE Proxy Card

MARIETTA, Ga., June 5, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the

Company ), an industry leader in advanced wound care and an emerging therapeutic biologics company, today released an investor presentation summarizing the reasons why the Company believes shareholders should support the Company s

three nominees for the Board of Directors (the Board ) at the 2018 annual meeting of shareholders that will take place on June 17, 2019.

Company s presentation highlights that the three Company nominees are all new to MiMedx and are experienced executives and board members at healthcare companies. One of the Company s nominees is MiMedx s new Chief Executive Officer.

The presentation also describes the Board s response to allegations of misconduct by the Company s former Chairman and CEO, Parker H.

( Pete ) Petit, and certain members of his senior management team. Among other things, as described in the presentation, the Board s Audit Committee conducted a thorough investigation with the assistance of outside counsel and

advisors that determined that Mr. Petit had engaged in material wrongdoing.

Nevertheless, Mr. Petit is seeking to be elected to the

Company s Board, together with two of his business associates. The presentation describes why the Board believes that the election of Mr. Petit would create significant issues for the Company with many of its key constituencies.

Other highlights of the MiMedx investor presentation include:

The MiMedx Board recommends that shareholders vote in

favor of the Company s three nominees, all of whom are experienced industry executives and new to MiMedx. Because the meeting is scheduled for less than two weeks from now, the Board encourages shareholders to vote online or by phone for all of

the Company s nominees as soon as they receive the Company s BLUE proxy card.

The investor presentation and other materials for

MiMedx s annual meeting of shareholders are available at www.VoteBlueforMiMedx.com.

Your Vote Is Important, No Matter How Many Or

How Few Shares You Own.

If you have questions about how to vote your shares, or need additional assistance, please contact the firm

assisting MiMedx in the solicitation of proxies:

INNISFREE M&A INCORPORATED

Shareholders may call toll-free at 1 (877) 800-5195

Banks and Brokers may call collect at 1 (212) 750-5833

MiMedx urges you NOT to sign any white proxy card sent to you by or on behalf of

Mr. Petit or his nominees.

If you have already done so, you have every legal right to change your vote by using the enclosed BLUE

proxy card to vote TODAY by telephone, by Internet or by signing, dating and returning the BLUE proxy card in the postage-paid envelope provided.

Sidley Austin LLP is acting as legal advisor to MiMedx.

MiMedx is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for

multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by

employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.5 million allografts to date. For additional information, please visit www.mimedx.com.

This communication includes forward-looking statements, including statements regarding the plan of MiMedx Group, Inc. (the Company ) to refresh the Board, the effects of such refreshment on the Company and expectations

with respect to Board leadership. Forward-looking statements may be identified by words such as believe, expect, may, plan, potential,

will, would and similar expressions and are based on current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions

investors against placing undue reliance on such statements.

Actual results may differ materially from those set forth in the forward-looking statements as a result of various factors, including the results of any election at the Company s 2018 annual meeting of shareholders (the 2018 Annual Meeting ) or the Company s

2019 annual meeting of shareholders (the 2019 Annual Meeting ). There is no assurance that the Board s nominees will be elected at the 2018 Annual Meeting or the 2019 Annual Meeting. Any

forward-looking statements speak only as of the date of this communication, and except as required by law, the Company assumes no obligation to update any

forward-looking statement, whether as a result of new information, future events or otherwise.

The Company has filed with the Securities and Exchange Commission (the SEC ) and is mailing to shareholders of

the Company a definitive proxy statement (the Proxy Statement ) and accompanying BLUE proxy card in connection with the solicitation of proxies for the 2018 Annual Meeting. The Proxy Statement is publicly available

and is being disseminated commencing on June 3, 2019. The Company, its directors, its director nominees and certain of its executive officers are participants in the solicitation of proxies from shareholders in respect of the 2018 Annual Meeting.

Information regarding the names of the Company s directors, director nominees and executive officers and their respective interests in the Company by security holdings or otherwise is set forth in the Proxy Statement. A free copy of the Proxy

Statement and other relevant documents that the Company files with the SEC may be obtained through the SEC s website at www.sec.gov or at the Company s website at https://mimedx.com/ as soon as reasonably practicable after such materials

are electronically filed with, or furnished to, the SEC.

Corporate & Investor Communications

Joele Frank, Wilkinson Brimmer Katcher

Repko / Annabelle Rinehart